Business Model Breakdown
How Hims & Hers Health Inc Makes Money
HIMS
Market Cap
$6.2B
Annual Revenue
$2.3B
Profit Margin
5.5%
Employees
1,637
The Short Version
Hims & Hers operates a direct-to-consumer telehealth platform, connecting individuals with licensed healthcare providers for consultations, diagnosis, and prescription fulfillment across various health categories like sexual health, dermatology, mental health, and weight management. The company generates revenue primarily through a subscription-based model, offering convenience, discretion, and access to personalized care and medications, including compounded and branded GLP-1 drugs, delivered directly to the customer's home.
Where the Revenue Comes From
Subscription fees for online consultations and ongoing care (~80-90% estimated)
Sales of prescription medications (including compounded GLP-1s) and over-the-counter products (~10-20% estimated)
Who buys: Consumers (primarily adults) seeking convenient, confidential, and affordable access to healthcare services and medications for sensitive or chronic conditions.
Why It Works (Competitive Advantages)
- ✔Strong direct-to-consumer brand recognition ('Hims' and 'Hers').
- ✔User-friendly and accessible digital telehealth platform.
- ✔Broad portfolio of conditions addressed, including high-demand areas like GLP-1s, mental health, and sexual health.
- ✔Positive cash flow generation providing financial flexibility.
Economic Moat: Narrow (Brand Power, Switching Costs, Network Effects)
What Our Analysis Says
DVR Score as of May 4, 2026
Hims & Hers retains growth potential driven by its D2C telehealth platform and positioning in chronic care like GLP-1s, evidenced by 59% YoY FY25 revenue growth and 2.5 million subscribers. However, the investment thesis for 10x growth within 3-5 years has significantly weakened since the last analysis. Intensified regulatory pressure on compounded GLP-1s directly threatens its fastest-growing segment. Critically, new data breach class-action lawsuits introduce substantial legal, reputational, and financial risks. Furthermore, a shift to a 'Hold' consensus by analysts and multiple price target reductions, alongside continued insider selling, indicate deteriorating market sentiment and increased uncertainty. These material negative factors substantially reduce its immediate high-reward potential and elevate the overall risk profile.